In vitro expansion of postpartum-derived cells in roller bottles
First Claim
Patent Images
1. A method of simultaneously maximizing doubling rate, harvest density, and the total number of population doublings for postpartum cells in a roller bottle culture system comprising:
- using a rotational speed from 0.65-0.9 rpm;
using at least 300 ml of growth medium in an 850 square centimeter culture bottle;
using a seeding density of less than 2,500 cells per square centimeter; and
incubating for between 5.5 to 6.5 days,wherein the postpartum cells that are cultured are characterized as having an identical marker profile as starting cells with respect to each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, HLA-ABC, CD31, CD34, CD45, CD117, CD141, and HLA-DRDPDQ, andwherein the postpartum cells are positive for expression of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-ABC, and negative for expression of CD31, CD34, CD45, CD117, CD141, and HLA-DRDPDQ.
3 Assignments
0 Petitions
Accused Products
Abstract
Methods for the maximizing parameter of the in vitro growth and expansion of mammalian cells, specifically postpartum-derived cells in containers such as roller bottles is described. Methods of optimizing growth rate and cell yield in such culture systems are provided. The methods are particularly adapted for human postpartum-derived cells, such as umbilicus-derived cells.
-
Citations
6 Claims
-
1. A method of simultaneously maximizing doubling rate, harvest density, and the total number of population doublings for postpartum cells in a roller bottle culture system comprising:
-
using a rotational speed from 0.65-0.9 rpm;
using at least 300 ml of growth medium in an 850 square centimeter culture bottle;using a seeding density of less than 2,500 cells per square centimeter; and incubating for between 5.5 to 6.5 days, wherein the postpartum cells that are cultured are characterized as having an identical marker profile as starting cells with respect to each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, HLA-ABC, CD31, CD34, CD45, CD117, CD141, and HLA-DRDPDQ, and wherein the postpartum cells are positive for expression of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, and HLA-ABC, and negative for expression of CD31, CD34, CD45, CD117, CD141, and HLA-DRDPDQ. - View Dependent Claims (2, 3, 4, 5, 6)
-
Specification